AUS
NZ
UK
CA
USA
IND
_10_04_2024_16_38_50_427275.jpg)
Highlights
- XRF Scientific's intrinsic value estimated at AU$2.02 per share.
- Current trading price suggests it's close to fair value.
- Peers are valued significantly higher, trading at a 185% premium.
Understanding a stock's intrinsic value can be crucial for investors focusing on long-term gains. Recently, XRF Scientific (ASX:XRF) was analyzed using the Discounted Cash Flow (DCF) model, revealing an intrinsic value estimate of AU$2.02. With its current trading price at AU$1.67, XRF Scientific appears to be trading close to this estimated fair value, offering potential insights for those with an interest in the stock market.
The analysis is built on the 2-stage free cash flow to equity model, considering the company's forecasted cash flows and a conservative discount rate to estimate today's value. The model assumes an initial higher growth phase transitioning to a more stable growth period, providing a comprehensive view beyond short-term market fluctuations.
Using analyst estimates and existing data, projected cash flows from 2025 to 2034 vary with a decreasing growth rate from 6.47% to 3.18%. These values are discounted at 7.1% to determine their present value, culminating in a ten-year projected cash flow of AU$91 million.
Additionally, a Terminal Value (TV) accounts for future cash flows beyond the initial decade, using a 2.7% growth rate aligned with government bond yields, resulting in a TV of AU$382 million. The present value of this terminal calculation yields AU$193 million, with a total equity value reaching approximately AU$284 million. Given these projections, XRF trades at around a 17% discount, indicating a potential alignment with its intrinsic worth.
Significant Assumptions and Market Context
The assumptions within this analysis consider a discount rate and cash flow projections, highlighting potential deviations influenced by industry cyclicality and other external factors. While examining XRF Scientific's potential, the cost of equity, factored at 7.1% with a levered beta of 0.996, underscores a stable comparative market volatility.
Complementary insights within a SWOT analysis reveal XRF's earnings growth surpassing industry benchmarks, while the dividend yield stays modest compared to top-paying entities in the Machinery sector. The firm’s current valuation and forecasted earnings growth provide promising prospects when compared to the broader Australian market landscape.
Understanding XRF Scientific's valuation involves not just a DCF analysis but should include various analytical perspectives and market sentiment among peers. This comprehensive view assists investors aiming for informed decisions backed by reliable data.
